Recombinetics

What Recombinetics does

Recombinetics is a US-based gene editing platform company founded in 2008 and headquartered in New Brighton, Minnesota, operating under the URUS Group holding structure. The company develops and applies proprietary TALENs and CRISPR/Cas9 technologies across two distinct verticals: biomedical preclinical research and agricultural precision breeding. Core technical capabilities include base-pair resolution gene editing, multiplex editing in primary cells, porcine induced pluripotent stem cells (iPSCs), bovine embryonic stem cells, and AI-enhanced bioinformatics for gene editor design.

The biomedical segment (Surrogen, Regenevida sub-brands) provides gene-edited swine models and preclinical services to pharmaceutical, biotech, and academic medical center customers for translational research, gene therapy development, oncology, and xenotransplantation. Notable commercial products include the Swine Reporter Models (SRM-1 and SRM-2) launched in 2024 for in vivo gene therapy and gene editing tracking. The agricultural segment operates through wholly-owned subsidiary Acceligen, which commercializes precision-bred founder animals for cattle, swine, and aquaculture markets globally, including SLICK heat-tolerant cattle, PRRSV-resistant pigs, and naturally castrated swine.

The business model combines professional services revenue (preclinical and custom gene editing engagements), product sales (swine models), licensing/royalties (Acceligen germplasm), and significant non-dilutive grant funding from NIH, NCI, the Bill & Melinda Gates Foundation, and FFAR. Customers include Mayo Clinic, American Preclinical Services, Hendrix Genetics, Kheiron-Biotech, Makana Therapeutics, and ReGen Theranostics. Go-to-market relies on direct enterprise sales, strategic partnerships, and a global conference presence (AACR, ASGCT, BIO).

Name

Recombinetics

Legal name

Recombinetics, Inc.

Website

https://recombinetics.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Recombinetics is a US-based gene editing company applying TALENs and CRISPR technologies to develop gene-edited swine models for biomedical preclinical research and precision-bred livestock for agricultural markets, serving pharma, biotech, academic medical centers, and global animal producers through subsidiaries Acceligen, Surrogen, and Regenevida.

Ownership category

akta.pro rank

Headquarters

HQ city

Eagan

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Preclinical Services: Complete pre-clinical solutions to gene therapy development, from cell editing to animal studies, including gene edited swine husbandry, veterinary oversight, and embryo transfer services. Recurring project-based engagements with biomedical and pharmaceutical customers.
2. Custom Gene Editing Services: Custom gene-edited products of the highest quality utilizing cutting-edge genome technologies paired with stringent QA/QC measures. Includes off-the-shelf and custom disease or reporter swine models for academic and commercial partners.
3. Swine Model Sales: Sale of gene-edited swine models including Swine Reporter Models (SRM-1, SRM-2) and disease models in large and minipig breeds to business partners, academic institutions, and internal research projects.
4. Grant Funding: Non-dilutive grant funding from government and foundations including NIH/NCI (e.g., $4M for glioblastoma swine model development), Bill & Melinda Gates Foundation (for African dairy), FFAR (for castration-free swine), and an SBIR grant from NIH for Osteogenesis Imperfecta research.
5. Precision Breeding & Livestock Traits (Acceligen): Commercialization of precision-bred founder animals that generate highly valued germplasm products for the global market, including climate-adapted and disease-resistant traits for cattle, swine, and aquaculture.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

Recombinetics develops and provides gene-edited animal models — primarily swine — and related gene editing services for biomedical research, preclinical drug development, xenotransplantation, and precision breeding of food animals. Leveraging proprietary TALENs and CRISPR/Cas9 platforms, the company sells swine models (including Swine Reporter Models and disease models), porcine iPSCs, and offers end-to-end preclinical and gene editing services to pharmaceutical, biotech, academic, and agricultural customers worldwide.

Product overview

Recombinetics operates a platform-plus-modules architecture centered on proprietary gene editing technologies (TALEN and CRISPR) applied across both biomedical and agricultural domains. The core product is gene-edited Swine Models, augmented by sub-products such as Swine Reporter Models (SRM-1, SRM-2) and Porcine Stem Cells (iPSCs), complemented by service modules including Preclinical Services, Gene Editing Services, and Support Services. The portfolio is organized under two sub-brands: Acceligen for agricultural/livestock applications (e.g., polled cattle, wool traits) and Therillume for preclinical brain cancer modeling, with cross-cutting capabilities in xenotransplantation donor pig development.

Differentiator

Problem solved

Functional benefit

Brands

• Acceligen: Wholly-owned subsidiary focused on precision breeding of food animals (cattle, swine, aquaculture) using gene editing, with operations including offices in Brazil.
• Surrogen
• Regenevida
• Therillume

Products and services

• Swine Models Gene-edited pig models designed for biomedical and translational research, including immunodeficient lines (e.g., EBT-3), humanized disease models, and xenotransplantation donor lines. Used by pharma, biotech, and academic researchers for preclinical studies.
• Swine Reporter Models (SRM-1, SRM-2) Reporter pig lines expressing bioluminescent and fluorescent markers (luciferase, fluorescent proteins) that enable in vivo tracking of cells, tumors, and disease progression for preclinical gene therapy and gene editing research.
• Porcine Stem Cells (iPSCs) Induced pluripotent stem cells (iPSCs) derived from porcine species using CRISPR-based reprogramming, supporting regenerative medicine, tissue engineering, disease modeling, and reproductive biotechnology research.
• Preclinical Services Contract research services providing in vivo pharmacology, toxicology, efficacy, and mechanistic studies using gene-edited swine models for biotech and pharmaceutical clients. Includes husbandry, veterinary oversight, and embryo transfer.
• Gene Editing Services Custom gene editing services using proprietary TALEN and CRISPR technologies to introduce, modify, or knock out specific genetic loci in livestock and biomedical animal models, with QA/QC and project delivery for academic and commercial partners.
• Therillume Brain Cancer Models Preclinical oncology offering providing orthotopic and bioluminescent swine brain cancer (glioma) models for translational brain tumor research and therapeutic evaluation. First preclinical test performed in Therillume brain tumor models in 2023.
• Acceligen Precision Breeding Commercialization of precision-bred founder animals that generate highly valued germplasm products for the global market, including climate-adapted, disease-resistant, and welfare-improved traits for cattle, swine, sheep, and aquaculture (e.g., SLICK heat tolerance, polled cattle, KISS1 castration-free swine).
• Support Services Ongoing scientific, technical, and husbandry support services provided alongside model licensing and preclinical engagements for gene-edited animal research customers.

Quantifiable outcome

• First commercial launch of swine reporter models for gene therapy development in 2024
• +9 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

• URUS Group (parent company)flagshipOthers · 16 September 2025URUS is the parent group; Recombinetics' privacy team is operated out of URUS ([email protected]). The privacy policy states data may be disclosed to URUS affiliates/subsidiaries.
• Makana TherapeuticscoreStrategic or Co-development Partner · 15 September 2021Makana Therapeutics received a $650,000 KidneyX Artificial Kidney Prize for work to increase the supply of kidney donor organs through pig-to-human xenotransplants, leveraging Recombinetics-derived gene-edited pigs.
• Mayo Clinic (Osteogenesis Imperfecta)coreStrategic or Co-development Partner · 1 July 2019Collaborative research project with Mayo Clinic to develop the first-ever swine models of Osteogenesis Imperfecta (brittle bone disease). Project led by Adrienne Watson, Ph.D. (Recombinetics VP of R&D) and Mayo Clinic's David Deyle, MD, partially funded by an SBIR grant from the National Institutes of Health.
• Kheiron-Biotech (Proinvesa Group)coreStrategic or Co-development Partner · 1 June 2019Joint projects in Argentina to produce multiple animal product lines combining Acceligen's gene-editing platform with Kheiron's in vitro embryo production, cloning, and gene-editing platform and infrastructure. Aimed at commercializing precision-bred founder animals with adaptability traits for climate change.
• TARGET-TB (Bovine Tuberculosis Research Consortium)minorStrategic or Co-development Partner · 1 October 2018Research collaboration to develop genome editing solutions for bovine tuberculosis (BTB).
• Hendrix Genetics (Hypor)flagshipStrategic or Co-development Partner · 1 April 2018Alliance to End Surgical Castration of Swine — combining Hendrix Genetics' commercially relevant swine genetics with Acceligen's proprietary precision breeding methods to develop naturally castrated male piglets. Alliance made possible by a grant from the Foundation for Food and Agriculture Research (FFAR).
• American Preclinical Services (APS)coreStrategic or Co-development Partner · 1 January 2018Partnership with American Preclinical Services to improve glioblastoma outcomes using Recombinetics' engineered swine models.
• Mayo Clinic (Regenerative Medicine)flagshipStrategic or Co-development Partner · 1 January 2017Multi-project collaborative R&D agreement with Mayo Clinic to bioengineer human stem cells within swine models for exo-transplantation back into humans. Combines Recombinetics' Regenevida biomedical swine with ReGen Theranostics' stem cells. Project leads: Dr. Timothy Nelson, M.D., Ph.D. (Mayo Clinic) and Dan Carlson, Ph.D. (Recombinetics SVP R&D).
• ReGen TheranosticscoreTechnology or Integration · 1 January 2017Provides quality control processes and high-quality stem cells used in the Mayo Clinic collaboration on exo-transplantation within Recombinetics' Regenevida swine models.
• UC DavisminorStrategic or Co-development Partner · 1 January 2017Research collaboration on the polled (hornless) cattle project; UC Davis conducted validation breeding of the first polled progeny and confirmed the FDA-discovered plasmid integration.

Scale indicators11 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• eGenesis: Gene-edited pig platform for xenotransplantation with PERV-knockout donor pigs. Most directly comparable to Recombinetics' biomedical/xenotransplantation thesis, including use of CRISPR in porcine models and pursuit of pig-to-human organ applications.
• Revivicor (United Therapeutics): Pioneered GalSafe pigs (FDA-approved) and 10-gene-edited pig hearts used in early human transplants. Closest historical precedent for Recombinetics' biomedical swine model and xenotransplantation work, with deeper clinical pipeline.
• Calyxt: Gene-editing platform applied to agricultural crops and livestock. Comparable to Acceligen's agricultural commercialization mission via TALEN/CRISPR-derived non-transgenic products, with a similar public-market journey (now private under Cibus merger).
• Pairwise: CRISPR-based agricultural company developing gene-edited fruits, row crops, and livestock with consumer and producer focus. Comparable to Acceligen's agricultural precision-breeding thesis and similar stage in commercializing non-GMO gene-edited products.

Broad incumbents

• Intrexon / Precigen: Diversified synthetic biology platform with gene-edited animal assets (e.g., EnviroFlight, AquaBounty salmon). Comparable as a broader incumbent in gene-edited animal commercialization spanning agricultural and biomedical markets.
• Genus plc: Global animal genetics leader in porcine and bovine breeding with PRRSV-resistant pig program (via PIC). Comparable to Acceligen as a customer/competitor in the precision-bred livestock space and as a potential strategic partner or acquirer.
• CRISPR Therapeutics: Leading clinical-stage CRISPR gene editing company with Casgevy approval. While focused on human therapeutics, its platform IP and large capital base position it as an adjacent/incumbent competitor for large-animal gene editing applications.

Emerging players

• Caribou Biosciences: Clinical-stage CRISPR genome editing company with allogeneic cell therapy pipeline. Comparable emerging player in next-generation gene editing applications, smaller than the major incumbents but technically credible.

Regional players

• Topigs Norsvin: Global pig genetics supplier with deep European footprint. Comparable to Acceligen's swine trait work and as a competing channel for gene-edited swine genetics, particularly relevant given Hendrix Genetics partnership.

Others

• MAKI Animal Clinic (Tonisity / Makana-aligned services): Veterinary and preclinical CRO services supporting large-animal research. Considered adjacent ecosystem participant for Recombinetics' biomedical preclinical services and gene-edited animal husbandry value chain.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/recombinetics-inc.
• Xx.com/Recombinetics
• Facebookfacebook.com/recombineticsinc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds12 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Recombinetics